Fulcrum Therapeutics, Inc. 8-K

What Happened
Fulcrum Therapeutics (FULC) filed a Form 8-K on January 12, 2026 reporting an estimated cash, cash equivalents and marketable securities balance of approximately $352.3 million as of December 31, 2025. The company noted this figure is preliminary, unaudited, based on management’s estimate and subject to completion of closing procedures; the independent auditor has not reviewed or audited the estimate. On the same day Fulcrum updated its corporate slide presentation and said management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (7:30 a.m. PT / 10:30 a.m. ET). A webcast and the slide deck (Exhibit 99.1) are available on Fulcrum’s investor site: https://ir.fulcrumtx.com.

Key Details

• Approx. $352.3 million in cash, cash equivalents and marketable securities as of Dec 31, 2025 (preliminary, unaudited).
• Filing date: January 12, 2026; presentation to be given Jan 14, 2026 at 7:30 a.m. PT (10:30 a.m. ET).
• Corporate presentation furnished as Exhibit 99.1 to the 8-K and available on the company’s investor site.
• Form 8-K signed by Alex C. Sapir, President and CEO.

Why It Matters
The disclosed cash position gives investors a snapshot of Fulcrum’s liquidity and financial condition heading into 2026, which is important for assessing runway for operations and clinical programs. The company’s updated presentation and JPMorgan conference appearance may provide additional strategic and business updates for investors; however, the cash figure is preliminary and unaudited, so final results may change when year-end financials are completed.